Assessment of multimodal treatment options in recurrent and persistent acromegaly: a systematic review and meta-analysis

被引:0
作者
Maroufi, Seyed Farzad [1 ,2 ]
Assar, Manijeh [3 ]
Khorasanizadeh, Mirhojjat [4 ]
Sabet, Fatemeh Mahdavi [1 ]
Sabahi, Mohammadmahdi [5 ]
Dabecco, Rocco [5 ]
Adada, Badih [5 ]
Zada, Gabriel [6 ]
Borghei-Razavi, Hamid [5 ,7 ]
机构
[1] Universal Sci Educ & Res Network USERN, Neurosurg Res Network NRN, Tehran, Iran
[2] Univ Tehran Med Sci, Dept Neurosurg, Tehran, Iran
[3] Univ Florida, Dept Surg, Jacksonville, FL USA
[4] Mt Sinai Hosp, Icahn Sch Med, Dept Neurosurg, New York, NY USA
[5] Cleveland Clin Florida, Pauline Braathen Neurol Ctr, Dept Neurol Surg, Weston, FL 33331 USA
[6] Univ Southern Calif, Keck Sch Med, Dept Neurosurg, Los Angeles, CA USA
[7] Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Surg, 2950 Cleveland Clin Blvd, Weston, FL 33331 USA
关键词
Acromegaly; Radiotherapy; Medical therapy; Trans-Sphenoidal surgery; Recurrence; Systematic review; Meta-analysis; TRANSSPHENOIDAL SURGERY; PITUITARY-ADENOMAS; GROWTH-HORMONE; RADIOSURGERY; RADIOTHERAPY; PREDICTORS; REMISSION;
D O I
10.1007/s11060-024-04658-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeIn patients with acromegaly, secondary treatment options in cases of hormonal non-remission or tumor progression include repeat transsphenoidal surgery (TSS), radiation-based treatment (RT), or medical therapy (MT). In this study, we aim to evaluate the clinical effectiveness of various second-line treatment options for acromegaly.MethodsUsing the PRISMA guideline, a systematic review was performed by searching MEDLINE (PubMed), Web of Science, Scopus, and Cochrane electronic bibliographic databases from conception to the end of 2022. Outcomes of interest included hormonal remission rate, complications, and mortality associated with each treatment modality for refractory acromegaly.ResultsA total of 79 studies including 3,208 refractory acromegaly patients (44.90% males) were analyzed, with a mean patient age of 43.89 years. There was a statistically significant difference between various therapeutic modalities in terms of remission rate, with MT offering the highest remission rate (62.55%), followed by RT (50.15%) and TSS (37.39%). Subgroup analysis of radiotherapeutic and medical modalities did not show a significant difference in remission rate between different kinds of sub-modalities in each treatment approach. Recurrence following secondary treatment was not different in patients treated with reoperation TSS compared to other modalities.ConclusionsThe management of persistent and recurrent acromegaly optimally requires a multimodal approach. In different scenarios of refractory acromegaly based on previous treatment, secondary treatments may vary in terms of remission rate and complications. Medical agents provide considerable effectiveness as a second-line therapy for recurrent or persistent disease. In selected cases, however, reoperation still provides an opportunity for cure or freedom from medications. The findings of this study may help clinicians to prioritize varying options involved in this multifaceted decision-making process.
引用
收藏
页码:13 / 25
页数:13
相关论文
共 29 条
  • [1] Reoperation for growth hormone-secreting pituitary adenomas: report on an endonasal endoscopic series with a systematic review and meta-analysis of the literature
    Almeida, Joao Paulo
    Ruiz-Trevino, Armando S.
    Liang, Buqing
    Omay, Sacit B.
    Shetty, Sathwik R.
    Md, Yu-Ning Chen
    Anand, Vijay K.
    Grover, Kartikey
    Christos, Paul
    Schwartz, Theodore H.
    [J]. JOURNAL OF NEUROSURGERY, 2018, 129 (02) : 404 - 416
  • [2] Long-Term Endocrine Outcomes Following Endoscopic Endonasal Transsphenoidal Surgery for Acromegaly and Associated Prognostic Factors
    Babu, Harish
    Ortega, Alicia
    Nuno, Miriam
    Dehghan, Aaron
    Schweitzer, Aaron
    Bonert, H. Vivien
    Carmichael, John D.
    Cooper, Odelia
    Melmed, Shlomo
    Mamelak, Adam N.
    [J]. NEUROSURGERY, 2017, 81 (02) : 357 - 366
  • [3] Berton AM, 2022, J CLIN MED, V12
  • [4] Bray DP, 2022, SURG ACROMEGALY INDI, V13
  • [5] The surgical treatment of acromegaly
    Buchfelder, Michael
    Schlaffer, Sven-Martin
    [J]. PITUITARY, 2017, 20 (01) : 76 - 83
  • [6] Radiotherapy and radiosurgery in acromegaly
    Castinetti, Frederic
    Morange, Isabelle
    Dufour, Henry
    Regis, Jean
    Brue, Thierry
    [J]. PITUITARY, 2009, 12 (01) : 3 - 10
  • [7] Predictors for Remission after Transsphenoidal Surgery in Acromegaly: A Dutch Multicenter Study
    Coopmans, Eva C.
    Postma, Mark R.
    Wolters, Thalijn L. C.
    van Meyel, Sebastiaan W. F.
    Netea-Maier, Romana
    van Beek, Andre P.
    Neggers, Sebastian J. C. M. M.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (06) : 1783 - 1792
  • [8] Approach to the Patient With Treatment-resistant Acromegaly
    Coopmans, Eva C.
    van der Lely, Aart J.
    Neggers, Sebastian J. C. M. M.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (06) : 1759 - 1766
  • [9] A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly
    Fleseriu, M.
    Zhang, Z.
    Hanman, K.
    Haria, K.
    Houchard, A.
    Khawaja, S.
    Ribeiro-Oliveira, A., Jr.
    Gadelha, M.
    [J]. PITUITARY, 2023, 26 (01) : 9 - 41
  • [10] The Role of Radiotherapy in Acromegaly
    Hannon, Mark J.
    Barkan, Ariel L.
    Drake, William M.
    [J]. NEUROENDOCRINOLOGY, 2016, 103 (01) : 42 - 49